{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:22:53Z","timestamp":1789993373435,"version":"4.0.1"},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The cost of topical treatments for actinic keratosis (<jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content>) has historically been evaluated in relation to the number of lesions requiring treatment or simply by the price of a single tube\/sachet of the drug used.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To demonstrate a new method of costing topical treatments in <jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content>, which takes into account the actual cancerization area treated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In order to evaluate the actual cost of each treatment, the official approval status of the drug was used to estimate the amount of cream needed per one cm<jats:sup>2<\/jats:sup>. This value was then applied to the hypothetical cancerization area sizes to demonstrate the impact of the size treated on the actual cost of treatment. The price considered was the ex\u2010factory price in Italy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Areas which could be treated with a single tube\/sachet of Metvix<jats:sup>\u00ae<\/jats:sup>, Picato<jats:sup>\u00ae<\/jats:sup>, Aldara<jats:sup>\u00ae<\/jats:sup>, Solaraze<jats:sup>\u00ae<\/jats:sup> and Zyclara<jats:sup>\u00ae<\/jats:sup> were 200, 25, 25, 33.3 and 200\u00a0cm<jats:sup>2<\/jats:sup>, respectively. For the treatment of smaller areas (&lt;100\u00a0cm<jats:sup>2<\/jats:sup>), treatment with Metvix<jats:sup>\u00ae<\/jats:sup> was the most costly topical option in Italy. However, for the treatment of cancerization areas larger than 100\u00a0cm<jats:sup>2<\/jats:sup>, Metvix<jats:sup>\u00ae<\/jats:sup> was the least expensive treatment option. Treatment with Metvix<jats:sup>\u00ae<\/jats:sup> was least long, requiring a single day of treatment for an area of up to 200\u00a0cm<jats:sup>2<\/jats:sup>, compared with up to 224\u00a0days of treatment with Aldara<jats:sup>\u00ae<\/jats:sup> for the treatment of a similar size.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Changing treatment costing strategy in the management of multiple <jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content>s towards costing per cancerization area instead of costing per lesion is a much more accurate representation of the \u2018real world cost\u2019 for AK.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.15269","type":"journal-article","created":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T03:29:15Z","timestamp":1538796555000},"page":"312-317","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of the treatment costs and duration of topical treatments for multiple actinic keratosis based on the area of the cancerization field and not on the number of lesions"],"prefix":"10.1111","volume":"33","author":[{"given":"P.","family":"Calzavara\u2010Pinton","sequence":"first","affiliation":[{"name":"Dermatology Department University of Brescia Brescia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Tanova","sequence":"additional","affiliation":[{"name":"Amaris London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hamon","sequence":"additional","affiliation":[{"name":"Galderma Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,10,23]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12434"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-014-0049-y"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13626"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14151"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475417702994"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07692.x"},{"key":"e_1_2_6_8_1","first-page":"651","article-title":"Development of a treatment algorithm for actinic keratoses: a European Consensus","volume":"18","author":"Stockfleth E","year":"2008","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14267"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03664.x"},{"key":"e_1_2_6_11_1","first-page":"539","article-title":"Real\u2010life practice study of the clinical outcome and cost\u2010effectiveness of photodynamic therapy using methyl aminolevulinate (MAL\u2010PDT) in the management of actinic keratosis and basal cell carcinoma","volume":"18","author":"Annemans L","year":"2008","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0211-7"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07483.x"},{"key":"e_1_2_6_14_1","unstructured":"Ltd GU.Metvix\u2122 160\u00a0mg\/g cream Summary of Product Characteristics. URLhttps:\/\/www.medicines.org.uk\/emc\/product\/6777\/smpc(last accessed 2018 12 April)."},{"key":"e_1_2_6_15_1","unstructured":"S.p.A LP.Picato\u2122 Summary of Product Characteristics. URLhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002275\/WC500135327.pdf(last accessed 2018 12 April)."},{"key":"e_1_2_6_16_1","unstructured":"S.p.A. MP.Aldara\u2122 5% cream Summary of Product CharacteristicsURLhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000179\/WC500023122.pdf(last accessed 2018 12 April)."},{"key":"e_1_2_6_17_1","unstructured":"S.p.A. MP.Zyclara\u2122 3.75% cream Summary of Product CharacteristicsURLhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002387\/WC500132261.pdf(last accessed 2018 12 April)."},{"key":"e_1_2_6_18_1","unstructured":"SA A.Solaraze\u2122 Summary of Product Characteristics. URLhttps:\/\/www.medicines.org.uk\/emc\/product\/6385\/smpc(last accessed 2018 12 April)"},{"key":"e_1_2_6_19_1","first-page":"35","article-title":"Non\u2010adherence to topical treatments for actinic keratosis","volume":"8","author":"Shergill B","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12840"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.15269","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.15269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T18:50:54Z","timestamp":1694717454000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.15269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,23]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1111\/jdv.15269"],"URL":"https:\/\/doi.org\/10.1111\/jdv.15269","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,23]]},"assertion":[{"value":"2018-07-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}